Canaccord Genuity maintains TransMedics Group at Buy, raises price target to $120 from $95

Canaccord Genuity kept its Buy rating on TransMedics Group and raised its price target to $120 from $95, citing a 74% potential upside from the Nov 5 close of $68.98.

Original reporting
Published Nov 6, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canaccord Genuity maintains TransMedics Group at Buy, raises price target to $120 from $95 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could attract short‑term buying interest, but without new operational news the move may be modest.

02

Market read

A modest but actionable catalyst for TMED investors.

03

What to watch

No new clinical data released; price may already reflect expectations.

Relevance 5/10Novelty 6/10Timing: pre‑market today

Background

Analyst rating updates are common catalysts for small‑cap biotech stocks.

Market effects

May lift sentiment in the biotech/medical device sector.

Limited to US biotech investors.

Low global impact.

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • Canaccord Genuity

    Equity research firm issuing the rating upgrade.

  • TransMedics Group

    US‑listed biotech focused on organ perfusion technologies.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.